A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC
Key facts
- Where
- 's-Gravenhage, Amsterdam, Apeldoorn, Dirksland, Dordrecht és Leiden, HollandiaSee the 6 sites
- Phase
- 3. fázis
Where in Hollandia
- Haga Hospital's-Gravenhage, HollandiaToborzás még nem indult
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, HollandiaToborzás még nem indult
- Gelre HospitalsApeldoorn, HollandiaToborzás még nem indult
- Het Van Weel-Bethesda ZiekenhuisDirksland, HollandiaToborzás még nem indult
- Albert Schweitzer ZiekenhuisDordrecht, HollandiaToborzás még nem indult
- Leids Universitair Medisch Centrum (LUMC)Leiden, HollandiaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Leids Universitair Medisch Centrum (LUMC)
- Trial code
- EU 2025-520792-67-00
- Record updated
- 2025. szeptember 12.
- Original description
To evaluate the efficacy of shorter duration of standard of care treatment ([chemo]immunotherapy) for patients with metastatic NSCLCRead full original descriptionShow less
To evaluate the efficacy of shorter duration of standard of care treatment ([chemo]immunotherapy) for patients with metastatic NSCLC
Inclusion: Advanced, metastatic non-small cell lung cancer UICC stage IV; Having received first line immunotherapy or first line (chemo)immunotherapy for 6 months ±2 weeks; Response or stable disease according to RECIST 1.1 as determined by imaging no older than 3 weeks at moment of randomization; Signed and dated informed consent; ECOG PS 0-2 and fit and willing to continue treatment with first line (chemo-)immunotherapy as deemed by the treating physician.
Exclusion: Any contra-indication (as per label) for treatment with immune checkpoint inhibitors; Other systemic anti-cancer treatment for the disease under study other than the first line (chemo-)immunotherapy.